ClinicalTrials.gov
ClinicalTrials.gov Menu

Bevacizumab Effect on Blood Velocity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01298440
Recruitment Status : Completed
First Posted : February 17, 2011
Last Update Posted : February 17, 2011
Sponsor:
Information provided by:
Optical Imaging, Ltd.

Brief Summary:
Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.

Condition or disease
Choroidal Neovascularization

Detailed Description:
The purpose of the study was to carry out a pilot study on the short-term effect of intravitreal Bevacizumab (Avastin) injection on retinal blood-flow velocity and test whether the short-term haemodynamic changes could predict the longer term clinical result of the treatment.

Study Type : Observational
Actual Enrollment : 12 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization
Study Start Date : January 2008
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources




Primary Outcome Measures :
  1. Blood flow velocity change [ Time Frame: 1 day following injection ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with choroidal neovascularization (CNV)
Criteria

Inclusion Criteria:

  • Patients with CNV receiving Bevacizumab intravitreal injection

Exclusion Criteria:

  • Candidates in whom the retina could not be seen clearly because of media opacity or a poorly dilating pupil

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01298440


Locations
Israel
Tel aviv sourasky medical center
Tel aviv, Israel, 64239
Sponsors and Collaborators
Optical Imaging, Ltd.
Investigators
Principal Investigator: Adiel Barak, MD Tel aviv university Sackler school of medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Optical Imaging, Ltd
ClinicalTrials.gov Identifier: NCT01298440     History of Changes
Other Study ID Numbers: AvastinRFI
First Posted: February 17, 2011    Key Record Dates
Last Update Posted: February 17, 2011
Last Verified: February 2011

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents